Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy
Open Access
- 3 May 2025
- journal article
- review article
- Published by Knowledge E DMCC in International Journal of Hematology-Oncology and Stem Cell Research
- Vol. 19 (2) , 180-190
Abstract
The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.Keywords
This publication has 48 references indexed in Scilit:
- Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHLBlood, 2016
- Multiple myeloma in the marrow: pathogenesis and treatmentsAnnals of the New York Academy of Sciences, 2016
- Multiple Myeloma: Diagnosis and TreatmentMayo Clinic Proceedings, 2016
- Blood transcriptomics and metabolomics for personalized medicineComputational and Structural Biotechnology Journal, 2015
- TRUCKs: the fourth generation of CARsExpert Opinion on Biological Therapy, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directionsThe Journal of Gene Medicine, 2012
- Documentation and Records: Harmonized GMP RequirementsJournal of Young Pharmacists, 2011
- Follicular lymphomaRevista Brasileira de Ginecologia e Obstetrícia, 2011
- Treatment of multiple myelomaBlood, 2004